Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia

Leukemia

Volumn 22, Issue 9, 2008, Pages 1685-1691

  Voso, M T ^a   Hohaus, S ^a   Guidi, F ^a   Fabiani, E ^a   D'Alo F ^a   Groner, S ^b   Spath D ^b   Doehner, K ^b   Leone, G ^a   Doehner, H ^b   Schlenk, R F ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; ISOLEUCINE; VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG FATALITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HEART DISEASE; HOMOZYGOSITY; HUMAN; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; THROMBOCYTE; THROMBOCYTE TRANSFUSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUTROPHILS; POLYMORPHISM, GENETIC; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 51649111870     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.169     Document Type: Article

References (44)

1. Salinas AE, Wong MG. Glutathione S-transferases - a review. Curr Med Chem 1999; 6: 279-309.
2. Shen H, Kauvar L, Tew KD. Importance of glutathione and associated enzymes in drug response. Oncol Res 1997; 9: 295-302.
3. Tew KD, Ronai Z. GST function in drug and stress response. Drug Resist Updat 1999; 2: 143-147.
4. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22: 7369-7375.
5. Wang W, Liu G, Zheng J. Human renal UOK130 tumor cells: A drug resistant cell line with highly selective over-expression of glutathione S transferase-pi isozyme. Eur J Pharmacol 2007; 568: 61-67.
6. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD et al. Regulation of JNK signaling by GSTp. EMBO J 1999; 18: 1321-1334.
7. Dorion S, Lambert H, Landry J. Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S transferase Mu from Ask1. J Biol Chem 2002; 277: 30792-30797.
8. Bernardini S, Bernassola F, Cortese C, Ballerini S, Melino G, Motti C et al. Modulation of GST P1-1 activity by polymerization during apoptosis. J Cell Biochem 2000; 77: 645-653.
9. Bernardini S, Bellincampi L, Ballerini S, Ranalli M, Pastore A, Cortese C et al. Role of GST P1-1 in mediating the effect of etoposide on human neuroblastoma cell line Sh-Sy5y. J Cell Biochem 2002; 86 340-347.
10. Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA et al Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19: 1279-1287.
11. Stanulla M, Schrappe M, Brechlin AM, Zimmerman M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study. Blood 2000; 95: 1222-1228.
12. Voso MT, D'Alo F, Putzulu R, Mele L, Scardocci A, Chiusolo P et al Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100: 2703-2707.
13. Schlenk RF, Dohner K, Pralle H, Götze K, Pfreundschuh M, Kneba M et al. Risk-adapted therapy in younger adults with acute myeloid leukemia: Results of the AMLHD98A trial of the AMLSG. Blood 2006; 108: [abstract 14].
14. Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18: 1798-1803.
15. Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: Results of second randomization of the AML HD98-B treatment Trial. Leukemia 2006; 20: 748-750.
16. Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG total AML HD98-B. Blood 2006; 108: 3280-3288.
17. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 641-644.
18. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
19. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
20. Welfare M, Monesola Adeokun A, Daly AK. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 289-292.
21. Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C et al. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 2001; 92: 220-225.
22. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006; 368 1894-1907.
23. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L et al. Mutations and outcome of treatment in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
24. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996; 24: 1015-1019.
25. Niitsu Y, Takahashi Y, Ban N, Takayama T, Saito T, Katahira T et al A proof of glutathione S-transferase-pi-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem Biol Interact 1998; 111-112: 325-332.
26. Morrow CS, Smitherman PK, Townsend AJ. Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol 1998; 56: 1013-1021.
27. Goto S, Ihara Y, Urata Y, Izumi S, Abe K, Koji T et al. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J 2001; 15: 2702-2714.
28. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994; 224 893-899.
29. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-280.
30. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999; 366: 89-94.
31. Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA et al Association between survival after treatment for breast cancer and glutathione S-transferase P1 IIe105Val polymorphism: Cancer Res 2000; 60: 5621-5624.
32. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC et al Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-942.
33. Hohaus S, Di Ruscio A, Di Febo A, Massini G, D'Alo F, Guidi F et al Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 2005; 11: 2175-2179.
34. Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005; 103: 52-58.
35. Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AF et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003; 102: 2345-2350.
36. Zhong S, Huang M, Yang X, Liang L, Wang Y, Romkes M et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 2006; 62: 457-472.
37. Yokomizo A, Yamamoto K, Kinukawa N, Tsunoda T, Koga H, Naito S. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy. Int J Urol 2007; 14: 500-504.
38. Gate L, Majumdar RS, Lunk A, Tew KD. Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase/STAT pathways. J Biol Chem 2004; 279: 8608-8616.
39. Jacobs-Helber SM, Sawyer ST. Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. Blood 2004; 104: 696-703.
40. Ruscoe JE, Rosario LA, Wang T, Gaé L, Arifoglu P, Wolf CR et al Pharmacologic or genetic mampulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 2001; 298: 339-345.
41. Stofega MR, Cheng M, Ma H, Sambucetti L, Keck JG, Brown GL et al. Telintra™ (TLK199) enhances granulocyte colony-stimulating factor production. Blood 2006; 108: [abstract 1161].
42. Raza A, Callander N, Ochoa L, Piro L, Emanuel P, Guba S et al. Hematologic improvement (HI) by TLK199 (Telintra™, a novel glutathione analog, in myelodysplastic syndrome: Phase 2 study results. Blood 2005; 106: [abstract 2520].
43. Raza A, Melcert M, Galili N, Smith SE, Godwin JE, Young S et al. Phase 1 dose escalation study of TLK199 tablets (Telintra), a novel glutathione analog, in myelodysplastic syndrome. Blood 2007; 110: [Abstract 1454].
44. Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS, Radloff GA et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002; 100: 67-71.